Bond.az White LogoBond.az Black Logo

JPMorgan Initiates Yesway Coverage with Neutral

JPMorgan initiates Yesway coverage with Neutral rating and $29 target. Details on earnings growth, valuation, and IPO news.

Lucas Garcia
ByLucas Garcia- Senior Editor
|
0

Bond.az - JPMorgan initiated coverage on Yesway Inc (NASDAQ:YSWY) with a Neutral rating and a price target of $29.00.

Analyst Thomas Palmer noted the company has grown earnings through same-store sales growth and inside margin expansion. The company's retail fuel margins are benefiting from a more volatile fuel price environment. Revenue reached $2.67 billion over the last twelve months, growing 5.8%.

JPMorgan expects earnings growth to benefit from accelerated unit growth and a shift toward larger, more profitable stores.

The Neutral rating reflects the company's valuation rather than concerns about underlying fundamentals. Currently trading at $25.84, the stock sits close to JPMorgan's $29 target. Yesway trades at premiums to convenience store peers MUSA and ATD on P/E and EV/EBITDA metrics, with an EV/EBITDA multiple of 9.56.

The company also trades above best-in-class CASY's historic average, despite carrying elevated debt levels relative to these peers and adding back items such as stock compensation in adjusted EPS and EBITDA. The company's debt-to-equity ratio stands at 1.69. Bond.az notes that liquid assets exceed short-term obligations.

In other recent news, Yesway priced its IPO at $20 per share, selling 14 million shares. After the IPO, shares opened at $22. Morgan Stanley, BMO Capital, and Goldman Sachs also provided ratings.

More News
Yesterday / 20:21
|
381

RBC Capital hikes Dominion Resources price target

RBC Capital raises Dominion price target to $72 on NextEra deal. Sector Perform rating maintained with 7% arbitrage spread.

0
Yesterday / 20:20
|
884

BofA raises Candel price target to $9

BofA raises Candel price target to $9 after 39% improvement in prostate cancer survival data.

0
Yesterday / 18:11
|
808

Roblox rebounds on user growth, Needham says

Needham reiterates Roblox Buy rating amid user growth rebound. Stock has 27% upside to $60 target.

0
Yesterday / 17:51
|
287

US Tiger Securities Boosts Baidu Price Target on AI

US Tiger Securities raised Baidu price target to $160 on AI growth. AI revenue now exceeds half of business.

0
Yesterday / 15:50
|
224

AMAT and LRCX stocks defended by Lynx

Lynx Equity defends AMAT and LRCX stocks with bullish price targets of $540 and $325 respectively.

0
Yesterday / 14:45
|
827

DA Davidson Maintains Brunswick Stock Neutral

DA Davidson reaffirms Neutral rating on Brunswick with $76 target. Premium brands strong, value brands weak. Q1 2026 results beat estimates.

0
Yesterday / 14:43
|
834

D.A. Davidson Reaffirms Aebi Schmidt on Strong Orders

D.A. Davidson reaffirms Buy rating on Aebi Schmidt with $15 target. Strong order backlog up 23%. Revenue beats expectations. Get details on Bond.az.

0
Yesterday / 13:32
|
366

Freedom Broker Upgrades Kinross Gold Rating

Freedom Broker upgrades Kinross Gold to Buy with $38 target. Strong cash flow and record margins drive the upgrade.

0
Yesterday / 13:01
|
960

JPMorgan Reiterates Five Below Stock Rating with $306 Target

JPMorgan reiterates Overweight rating on Five Below with $306 price target, implying 43% upside potential.

0
Yesterday / 11:44
|
685

Elmet Stock Gets Overweight Rating

Cantor Fitzgerald starts Elmet Group with Overweight rating and $20 target. Defense and reshoring trends drive outlook.

0
Yesterday / 11:25
|
722

Truist Starts Arcus Biosciences at Buy on RCC Potential

Truist Securities initiates Arcus Biosciences with Buy rating and $35 price target, citing casdatifan's potential in renal cell carcinoma and immunology pipeline.

0
Yesterday / 11:24
|
728

Revolution stock buy rating from Truist

Truist Securities gives Revolution Medicines a buy rating with a $179 price target. Daraxon's potential and company outlook.

0
...